Skip to main content
ADIAL PHARMACEUTICALS, INC. logo

ADIAL PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · ADIL ISIN · US00688A1060 US Manufacturing
Open in API
Filings indexed 520 across all filing types
Latest filing 2026-05-11 Earnings Release
Country US United States of America
Listing US ADIL

About ADIAL PHARMACEUTICALS, INC.

https://www.adialpharma.com/

Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of therapies for the treatment and prevention of addiction and related disorders. The company's lead investigational drug candidate is AD04, a genetically targeted, serotonin-3 receptor antagonist for the treatment of Alcohol Use Disorder (AUD). AD04 is being developed in conjunction with a proprietary companion diagnostic genetic test. This test is designed to identify patients with specific genotypes who are most likely to respond to the treatment, representing a personalized medicine approach to managing addiction.

Recent filings

Filing Released Lang Actions
8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
Earnings Release Classification · 93% confidence The document is a Form 8-K current report filed under Item 2.02 (“Results of Operations and Financial Condition”) reporting that the company issued a press release with its quarterly financial information for the period ended March 31, 2026. This is the initial announcement of quarterly financial results (a press release attached as Exhibit 99.1), which matches the definition of an Earnings Release (ER). Q1 2026
2026-05-11 English
8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC by Adial Pharmaceuticals, Inc. It reports on a collaboration framework agreement with Molteni Farmaceutici and details about a Special Meeting of Stockholders that was called but not convened due to lack of quorum. The document includes a press release as an exhibit and discusses business developments and shareholder meeting events. There are no financial statements or detailed financial data presented, nor is this a full annual or quarterly report. The content is primarily an announcement of material events and agreements, typical of a Current Report (8-K). Given the nature of the filing and the absence of financial statements or earnings data, the appropriate classification is Regulatory Filings (RNS).
2026-03-03 English
8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Adial Pharmaceuticals, Inc. It reports that the company has regained compliance with Nasdaq's minimum bid price requirement. The document includes a notice from Nasdaq and a press release attached as an exhibit. There are no financial statements or detailed financial data included, and the document is relatively short (4429 characters). It is an announcement of an event (regaining compliance with listing rules) rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance-related filings that do not fit other categories.
2026-02-24 English
8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 3, 2026, by Adial Pharmaceuticals, Inc. It reports a material event: a reverse stock split approved by stockholders and implemented by amendment to the Certificate of Incorporation. The document details the reverse stock split ratio, effective date, and trading symbol changes. It also includes a press release as an exhibit. The content focuses on a capital structure change (reverse stock split) and related corporate actions. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document is not an annual or quarterly report, audit report, or earnings release, nor is it a voting result or management change announcement. It is a regulatory filing but specifically about a capital structure change, so CAP is the most precise classification. Confidence is high given the clear description of the reverse stock split and related amendments.
2026-02-04 English
CURRENT REPORT
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 5, 2026, reporting the resignation of a board member, James W. Newman, Jr. The key content is about the departure of a director from the company's board. There are no financial statements, earnings data, or detailed management discussion. The primary focus is on a change in the company's board of directors. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under the category 'Board/Management Information' (MANG). The document length is 3682 characters, which is relatively short and consistent with a typical 8-K announcement of management changes. Therefore, the appropriate classification is MANG with high confidence.
2026-01-06 English
DEFINITIVE PROXY STATEMENT
Proxy Solicitation & Information Statement
2026-01-06 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.